rs374628465
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_001114753.3(ENG):c.690-5C>T variant causes a splice region, splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000491 in 1,609,634 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001114753.3 splice_region, splice_polypyrimidine_tract, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ENG | NM_001114753.3 | c.690-5C>T | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | ENST00000373203.9 | NP_001108225.1 | |||
ENG | NM_000118.4 | c.690-5C>T | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | NP_000109.1 | ||||
ENG | NM_001278138.2 | c.144-5C>T | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | NP_001265067.1 | ||||
ENG | NM_001406715.1 | c.690-5C>T | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | NP_001393644.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ENG | ENST00000373203.9 | c.690-5C>T | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | 1 | NM_001114753.3 | ENSP00000362299 | P2 | |||
ENG | ENST00000344849.4 | c.690-5C>T | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | 1 | ENSP00000341917 | A2 | ||||
ENG | ENST00000480266.6 | c.144-5C>T | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | 2 | ENSP00000479015 |
Frequencies
GnomAD3 genomes AF: 0.0000200 AC: 3AN: 150074Hom.: 0 Cov.: 26
GnomAD3 exomes AF: 0.0000403 AC: 10AN: 247854Hom.: 0 AF XY: 0.0000297 AC XY: 4AN XY: 134548
GnomAD4 exome AF: 0.0000521 AC: 76AN: 1459560Hom.: 0 Cov.: 33 AF XY: 0.0000482 AC XY: 35AN XY: 726138
GnomAD4 genome AF: 0.0000200 AC: 3AN: 150074Hom.: 0 Cov.: 26 AF XY: 0.0000274 AC XY: 2AN XY: 73074
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 16, 2023 | Variant summary: ENG c.690-5C>T alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-05 in 247854 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in ENG causing Hereditary Hemorrhagic Telangiectasia (4e-05 vs 4.2e-05), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.690-5C>T in individuals affected with Hereditary Hemorrhagic Telangiectasia and no experimental evidence demonstrating its impact on protein function have been reported. One submitter has cited clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 13, 2022 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Hereditary hemorrhagic telangiectasia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 05, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at